Beijing Northland Biotechnology Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted marketing approval for engensis, a naked plasmid gene therapy, for the treatment of limb ulcers caused by severe lower limb ischemia in patients unsuitable for revascularization surgery or with poor surgical outcomes. The therapy addresses critical unmet needs in atherosclerosis obliterans, thromboangiitis obliterans, and diabetic lower limb ischemia.
Regulatory Milestone & Clinical Indication
Parameter
Detail
Regulatory Agency
NMPA (China)
Approval Type
Marketing authorization
Indication
Limb ulcers from severe lower limb ischemia
Patient Population
Unsuitable for revascularization surgery or poor surgical outcomes
Etiologies Covered:
• Atherosclerosis obliterans
✓
• Thromboangiitis obliterans
✓
• Diabetic lower limb ischemia
✓
Drug Profile & Mechanism of Action
Therapy Class: Naked plasmid gene therapy
Vector System: pCK vector with efficient target gene expression
Active Component: Hybrid hepatocyte growth factor gene (HGF-X7)
Administration: Intramuscular injection
Cellular Target: Striated muscle cells
Molecular Mechanism
Gene Expression: Transfected muscle cells express and secrete two HGF isoforms (HGF723 and HGF728)
Receptor Binding: HGF proteins bind to c-Met tyrosine kinase receptor on vascular endothelial cells
Biological Effects:
Stimulates endothelial cell proliferation
Promotes migration of endothelial and smooth muscle cells
Induces local angiogenesis
Establishes collateral circulation
Improves lower limb blood perfusion
Pivotal Phase III Clinical Evidence
HOPE CLTI-2 Study Results
Endpoint
Result
Significance
Primary Endpoint
Complete ulcer healing rate
Significantly higher vs. placebo
Safety Profile
Adverse events
Similar to placebo
Patient Population
Severe lower limb ischemia with limb ulcers
High unmet medical need
Treatment Paradigm
Non-surgical option for revascularization-ineligible patients
Addresses critical gap in care
Market Opportunity & Therapeutic Context
Critical Limb Ischemia Landscape in China
Patient Burden: Estimated 2-3 million patients with severe lower limb ischemia
Surgical Limitations: 30-40% of patients unsuitable for revascularization procedures
Current Treatment Gaps: Limited effective non-surgical options for ulcer healing
Amputation Risk: High rates of major amputation without effective intervention
Competitive Therapeutic Approaches
Approach
Current Options
Limitations
Engensis Advantage
Revascularization Surgery
Bypass, endovascular procedures
30-40% ineligible, high complication rates
Non-surgical alternative
Wound Care
Standard dressings, debridement
Limited efficacy in ischemic ulcers
Addresses underlying ischemia
Growth Factor Therapies
Limited availability
Short half-life, repeated administration
Sustained local HGF expression
Cell Therapies
Experimental approaches
Complex manufacturing, regulatory hurdles
Simple plasmid-based gene therapy
Strategic Implications
For Northland Biotechnology
First-in-Class Status: First approved gene therapy for lower limb ischemia in China
Commercial Pioneer: Establishes leadership in cardiovascular gene therapy market
Manufacturing Advantage: Plasmid-based approach enables scalable, cost-effective production
Global Potential: Positive Phase III data supports international regulatory filings
China Cardiovascular Gene Therapy Market
Regulatory Innovation: NMPA approval reflects evolving framework for advanced therapies
Healthcare Economics: Potential to reduce amputation costs and improve quality of life
Reimbursement Pathway: High clinical value may support premium pricing and NRDL inclusion
Physician Education: Need for training on gene therapy administration and patient selection
Implementation Strategy & Commercial Outlook
Market Launch Timeline: Expected Q3-Q4 2026
Target Facilities: Vascular surgery centers, wound care clinics, diabetes foot centers
Distribution Model: Direct sales force with specialized training requirements
Revenue Potential: Estimated ¥400-600 million annual peak sales in Chinese CLI market
Forward-Looking Statements This brief contains forward-looking statements regarding market launch, commercial performance, and regulatory compliance for engensis. Actual results may differ due to risks including market adoption challenges, healthcare policy changes, competitive dynamics, and evolving standards of care for critical limb ischemia.-Fineline Info & Tech
By Fineline Cube